Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
| Condition | Smoldering Plasma Cell Myeloma |
|---|---|
| Phase | Early Phase 1 |
| Sponsor | M.D. Anderson Cancer Center |
| Status | Active, not recruiting |
| Enrollment | 20 participants |
| Interventions | Laboratory Biomarker Analysis, Pembrolizumab |
| Start date | Jul 20, 2016 |
| Completion date | Dec 30, 2017 |
| Results posted | Mar 20, 2020 |
Summary
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Overall Response Rate (ORR)
| Treatment (Pembrolizumab) | 1 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (M — National Cancer Institute (NCI)